Case Reports in Dermatological Medicine最新文献_第6页

Treatment of Generalized Granuloma Annulare with Oral Griseofulvin. 口服灰黄霉素治疗广泛性环形肉芽肿。

Case Reports in Dermatological Medicine Pub Date : 2022-11-18 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2523710

Chumsaeng Chumsaengsri, Jongjin Suwanthaweemeesuk

{"title":"Treatment of Generalized Granuloma Annulare with Oral Griseofulvin.","authors":"Chumsaeng Chumsaengsri, Jongjin Suwanthaweemeesuk","doi":"10.1155/2022/2523710","DOIUrl":"https://doi.org/10.1155/2022/2523710","url":null,"abstract":"Background: Granuloma annulare (GA) is a benign skin disease that has four clinical variants including localized, generalized, perforating, and subcutaneous GA. The most common type is localized GA, followed by generalized GA. Generalized GA was defined as at least 10 widespread annular plagues and frequently on the trunk, face, neck, and extremities. The diagnosis was made by clinical and histopathology. Generalized GA was difficult to treat. Case Presentation. We presented a Thai woman with nonscaly annular papules and plaques on the trunk and all extremities. A skin biopsy revealed a lesion that was compatible with granuloma annulare. She was partially resolved with 2-month course of oral griseofluvin 500 mg daily. Discussion. The regression of GA response to oral griseofulvin is consistent with the inflammatory nature, which identified IFN-gamma upregulated in GA.Conclusion: Griseofulvin is safe with few side effects and cost effectiveness. Further studies are needed to better understand the immunology and pathogenesis of GA.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"2523710"},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40488165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aggressive Acute Marjolin's Ulcer Arising in a Burn Scar. 烧伤瘢痕引起的侵袭性急性马氏溃疡。

Case Reports in Dermatological Medicine Pub Date : 2022-11-08 eCollection Date: 2022-01-01 DOI: 10.1155/2022/8329050

Adela Alvarez Rio, Josep Oriol Roca Mas, Daniel Navarro Sanchez, Ivan Monge Castresana, Gonzalo Joaquin Soroa Moreno, Jaime Estrada Cuxart

引用次数: 1

Amelanotic Melanoma Treated as Fungal Infection for Years. 无色素黑色素瘤作为真菌感染治疗多年。

Case Reports in Dermatological Medicine Pub Date : 2022-11-07 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2598965

Guilherme Kuceki, Dekker C Deacon, Aaron M Secrest

引用次数: 1

Giant Dermatofibroma: A Rare Presentation as a Large Scaly Plaque. 巨大皮肤纤维瘤:一种罕见的大鳞状斑块。

Case Reports in Dermatological Medicine Pub Date : 2022-10-26 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2542404

T Iqbal, V Mudaliar

引用次数: 0

New-Onset Lichen Planus Induced by the Pfizer COVID-19 Vaccine. 新冠肺炎疫苗致新发扁平苔藓的研究

Case Reports in Dermatological Medicine Pub Date : 2022-09-17 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2082445

Fadi A Alghamdi, Shahad T Khayyat, Mohammed M Alshareef, Wala'a Felemban

{"title":"New-Onset Lichen Planus Induced by the Pfizer COVID-19 Vaccine.","authors":"Fadi A Alghamdi, Shahad T Khayyat, Mohammed M Alshareef, Wala'a Felemban","doi":"10.1155/2022/2082445","DOIUrl":"https://doi.org/10.1155/2022/2082445","url":null,"abstract":"Objective: Coronavirus disease 2019 (COVID-19) vaccine distribution continues to expand; however, increased cutaneous reactions have been reported. Several recent studies suggest a link between COVID-19 vaccination and the development of various cutaneous complications. Lichen planus is a chronic, immune-mediated, inflammatory dermatological illness with an unclear etiology. In this case report, we assessed the relationship between COVID-19 vaccination (Pfizer) and lichen planus diagnosis and evaluated the link between additional doses of the vaccine and disease progression.Methods: Complete clinical, laboratory, and histopathological assessment of a patient was performed with ethical and privacy considerations. Written informed consent for all clinical data, images, and publication was obtained from the patient.Results: New-onset lichen planus appeared 48 hours after the first dose of the Pfizer vaccine. The symptoms worsened following the second dose. The patient responded gradually to topical corticosteroids, and lichen planus was controlled within 21 days.Conclusion: Our case significantly contributes to the literature by highlighting that additional doses of the Pfizer vaccine can contribute to disease progression. Therefore, reporting the patient's condition associated with COVID-19 vaccination should be considered. Future studies should be performed to investigate the combined onset of lichen planus and multisystem COVID-19 vaccine-related complications.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"2082445"},"PeriodicalIF":0.0,"publicationDate":"2022-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40375258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Interstitial Mycosis Fungoides: An Unusual Mimic of Interstitial Granuloma Annulare Not to Miss. 间质性蕈样真菌病:一种不寻常的间质性肉芽肿的模拟物。

Case Reports in Dermatological Medicine Pub Date : 2022-09-05 eCollection Date: 2022-01-01 DOI: 10.1155/2022/3506738

Neha Singh, Kiley K Fagan, Douglas J Grider

{"title":"Interstitial Mycosis Fungoides: An Unusual Mimic of Interstitial Granuloma Annulare Not to Miss.","authors":"Neha Singh, Kiley K Fagan, Douglas J Grider","doi":"10.1155/2022/3506738","DOIUrl":"https://doi.org/10.1155/2022/3506738","url":null,"abstract":"Interstitial mycosis fungoides is a rare histopathologic variant of mycosis fungoides that may resemble interstitial granuloma annulare, inflammatory morphea, and interstitial granulomatous dermatitis. Reported is a case of a 62-year-old African American female who presented with an asymptomatic, progressive rash of the left underarm and abdomen with histologic features suggestive of granuloma annulare. Biopsies revealed an interstitial pattern of cells in the dermis with prominent small aggregates of atypical lymphocytes, a few atypical lymphocytes in the lower epidermis, and a mild increase in dermal mucin. Immunohistochemistry staining revealed the atypical lymphocytes to be positive for CD3 and CD8 and negative for CD4 and CD7, an aberrant immunoprofile. Mixed in the dermis with the atypical lymphoid cells were a few CD68 positive histiocytes and S100 protein positive dermal dendritic cells. T-cell receptor beta gene rearrangement studies showed nearly the same clonal peaks for TCRB rearrangement in two biopsy specimens from separate sites, all supporting a diagnosis of interstitial mycosis fungoides. The patient is undergoing treatment with full body narrowband UVB (nbUVB) phototherapy with notable improvement in skin discoloration and resolution of several abdominal lesions. A diagnosis of interstitial mycosis fungoides is challenging to make based on clinical features alone and is often clinically misdiagnosed. Awareness of histopathologic features is critical to make an accurate diagnosis and thus patient management.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"3506738"},"PeriodicalIF":0.0,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40357970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID-19 Vaccination. COVID-19疫苗接种后寻常型天疱疮和扁平苔藓的共存。

Case Reports in Dermatological Medicine Pub Date : 2022-08-28 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2324212

Zeinab Aryanian, Kamran Balighi, Arghavan Azizpour, Kambiz Kamyab Hesari, Parvaneh Hatami

引用次数: 4

Pityriasis Versicolor Resistant to Antifungal Drugs in a Patient in Lomé (Togo). 多哥洛莫雷市1例花斑糠疹抗真菌药物耐药。

Case Reports in Dermatological Medicine Pub Date : 2022-08-22 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5404913

Julienne Teclessou, Koussake Kombate, Bayaki Saka, Séfako Abla Akakpo, Palokinam Pitche

{"title":"Pityriasis Versicolor Resistant to Antifungal Drugs in a Patient in Lomé (Togo).","authors":"Julienne Teclessou, Koussake Kombate, Bayaki Saka, Séfako Abla Akakpo, Palokinam Pitche","doi":"10.1155/2022/5404913","DOIUrl":"https://doi.org/10.1155/2022/5404913","url":null,"abstract":"Background: Pityriasis versicolor (PV) is a ubiquitous superficial skin mycosis that often affects young adults. It is often effectively treated with local or oral antifungal agents. Cases of PV resistance to antifungal agents have been reported rarely. We report a case of antifungal resistant PV. Observation. A 22-year-old patient was followed since the age of 17 years in a dermatology outpatient clinic for hyperpigmented scaly macular lesions of the trunk and upper limbs. The clinical diagnosis of PV was retained. The patient was treated by fluconazole 300 mg/week before being lost to follow-up. He was seen again in 2019 (about 2 years later) for the same symptomatology and treated again by fluconazole and ciclopirox olamine cream without improvement. He was again lost to follow-up and seen again six months later. A mycological sample was taken and Aspergillus niger was isolated. The patient was treated by itraconazole for 6 weeks. The evolution was marked by a clinical status quo. The patient was again put on salicylated petroleum jelly 10% associated with terbinafine cream and then lost to follow-up.Conclusion: The emergence of fungal resistance to antifungal drugs does not spare PV. It can therefore be resistant to several antifungal drugs, leaving clinicians and patients in despair.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"5404913"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40332472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nasolabial Ulcerated Placard Revealing a Primary Cutaneous Aggressive Epidermotropic CD8+ T-cell Lymphoma. 鼻唇溃疡牌显示原发性皮肤侵袭性表皮性CD8+ t细胞淋巴瘤。

Case Reports in Dermatological Medicine Pub Date : 2022-08-09 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5672783

J B Ntihebuwayo, F Hali, A Kerouach, H Rachadi, S Chiheb, F Marnissi

{"title":"Nasolabial Ulcerated Placard Revealing a Primary Cutaneous Aggressive Epidermotropic CD8+ T-cell Lymphoma.","authors":"J B Ntihebuwayo, F Hali, A Kerouach, H Rachadi, S Chiheb, F Marnissi","doi":"10.1155/2022/5672783","DOIUrl":"https://doi.org/10.1155/2022/5672783","url":null,"abstract":"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma is a rare entity representing less than 1% of cutaneous lymphomas. It has an aggressive clinical manifestation with a poor prognosis. It is characterized by cytotoxic and epidermotropic CD8+ proliferation. It also expresses the TIA-1 marker. We report a new case for its display and aggressive character, diagnostic difficulty, and good therapeutic response to chemotherapy. This is a 62-year-old female patient admitted to the hospital for a nasolabial ulcerated placard evolving for two years. Clinical examination revealed submandibular lymph nodes. The specimen analysis associated with anatomoclinical manifestation was concluded for a primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. Tumor extent assessment did not show any secondary localization. The blood tests and serology were unremarkable. The patient had benefited from a CHOEP-type multidrug therapy protocol with complete healing of the lesion after three courses of chemotherapy.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"5672783"},"PeriodicalIF":0.0,"publicationDate":"2022-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40624255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leukocytoclastic Vasculitis following the First Dose of the Elasomeran COVID-19 Vaccination. 第一剂新冠肺炎疫苗接种后的白细胞破裂性血管炎。

Case Reports in Dermatological Medicine Pub Date : 2022-08-04 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1469410

Jarett J Casale, Mikél E Muse, Tara J Snow, Karen P Gould, Natalie D Depcik-Smith

{"title":"Leukocytoclastic Vasculitis following the First Dose of the Elasomeran COVID-19 Vaccination.","authors":"Jarett J Casale, Mikél E Muse, Tara J Snow, Karen P Gould, Natalie D Depcik-Smith","doi":"10.1155/2022/1469410","DOIUrl":"https://doi.org/10.1155/2022/1469410","url":null,"abstract":"Our case highlights leukocytoclastic vasculitis as a potential side effect of the elasomeran COVID-19 vaccine. As the elasomeran vaccine becomes more widely available to the public, cutaneous reactions should be noted and looked for as potential side effects of the vaccine. Our patient had a history of immune thrombocytopenic purpura, making this a potential predisposing condition to the development of vasculitis following elasomeran administration. The case of vasculitis in our patient, although diffuse in distribution, was self-resolving. Our patient was counseled of the potential risk of worsening reaction to the second dose of the vaccine and instructed to proceed at their own risk. He elected to receive the second vaccination dose without any further reaction or side effects. Primary teaching points from this case include the potential of developing leukocytoclastic vasculitis following the elasomeran vaccination. Patients who develop LCV following the first dose should be counseled of the risks associated with receiving the second dose, including progression to systemic organ involvement.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":" ","pages":"1469410"},"PeriodicalIF":0.0,"publicationDate":"2022-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40613211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1